615 related articles for article (PubMed ID: 28361189)
1. Personalized
Del Prete M; Buteau FA; Beauregard JM
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1490-1500. PubMed ID: 28361189
[TBL] [Abstract][Full Text] [Related]
2. Personalized
Del Prete M; Buteau FA; Arsenault F; Saighi N; Bouchard LO; Beaulieu A; Beauregard JM
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):728-742. PubMed ID: 30506283
[TBL] [Abstract][Full Text] [Related]
3. Accuracy and reproducibility of simplified QSPECT dosimetry for personalized
Del Prete M; Arsenault F; Saighi N; Zhao W; Buteau FA; Celler A; Beauregard JM
EJNMMI Phys; 2018 Oct; 5(1):25. PubMed ID: 30318563
[TBL] [Abstract][Full Text] [Related]
4. Salvage peptide receptor radionuclide therapy with [
van der Zwan WA; Brabander T; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; Krenning EP; de Herder WW
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):704-717. PubMed ID: 30267116
[TBL] [Abstract][Full Text] [Related]
5. Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course.
Bergsma H; Konijnenberg MW; Kam BL; Teunissen JJ; Kooij PP; de Herder WW; Franssen GJ; van Eijck CH; Krenning EP; Kwekkeboom DJ
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):453-63. PubMed ID: 26419852
[TBL] [Abstract][Full Text] [Related]
6. 177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function.
Ranade R; Basu S
J Nucl Med Technol; 2016 Jun; 44(2):65-9. PubMed ID: 26848166
[TBL] [Abstract][Full Text] [Related]
7. Prospective observational study of
Garske-Román U; Sandström M; Fröss Baron K; Lundin L; Hellman P; Welin S; Johansson S; Khan T; Lundqvist H; Eriksson B; Sundin A; Granberg D
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):970-988. PubMed ID: 29497803
[TBL] [Abstract][Full Text] [Related]
8. Salvage PRRT with
Rudisile S; Gosewisch A; Wenter V; Unterrainer M; Böning G; Gildehaus FJ; Fendler WP; Auernhammer CJ; Spitzweg C; Bartenstein P; Todica A; Ilhan H
BMC Cancer; 2019 Aug; 19(1):788. PubMed ID: 31395036
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.
Valkema R; Pauwels SA; Kvols LK; Kwekkeboom DJ; Jamar F; de Jong M; Barone R; Walrand S; Kooij PP; Bakker WH; Lasher J; Krenning EP
J Nucl Med; 2005 Jan; 46 Suppl 1():83S-91S. PubMed ID: 15653656
[TBL] [Abstract][Full Text] [Related]
10. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment.
Sandström M; Garske-Román U; Granberg D; Johansson S; Widström C; Eriksson B; Sundin A; Lundqvist H; Lubberink M
J Nucl Med; 2013 Jan; 54(1):33-41. PubMed ID: 23223392
[TBL] [Abstract][Full Text] [Related]
11. Can peptide receptor radionuclide therapy be safely applied in florid bone metastases? A pilot analysis of late stage osseous involvement.
Sabet A; Khalaf F; Yong-Hing CJ; Sabet A; Haslerud T; Ahmadzadehfar H; Guhlke S; Grünwald F; Biersack HJ; Ezziddin S
Nuklearmedizin; 2014; 53(2):54-9. PubMed ID: 24777355
[TBL] [Abstract][Full Text] [Related]
12. Early prediction of tumour response to PRRT. The sequential change of tumour-absorbed doses during treatment with 177Lu-octreotate.
Ezziddin S; Reichmann K; Yong-Hing C; Damm M; Risse J; Ahmadzadehfar H; Logvinski T; Guhlke S; Biersack HJ; Sabet A
Nuklearmedizin; 2013; 52(5):170-7. PubMed ID: 23963021
[TBL] [Abstract][Full Text] [Related]
13. Peptide receptor radionuclide therapy with 177Lu-DOTA-octreotate: dosimetry, nephrotoxicity, and the effect of hematological toxicity on survival.
Löser A; Schwarzenböck SM; Heuschkel M; Willenberg HS; Krause BJ; Kurth J
Nucl Med Commun; 2018 Mar; 39(3):236-246. PubMed ID: 29315138
[TBL] [Abstract][Full Text] [Related]
14. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate.
Sabet A; Ezziddin K; Pape UF; Ahmadzadehfar H; Mayer K; Pöppel T; Guhlke S; Biersack HJ; Ezziddin S
J Nucl Med; 2013 Nov; 54(11):1857-61. PubMed ID: 24009272
[TBL] [Abstract][Full Text] [Related]
15. Safety of multiple repeated cycles of
Yordanova A; Mayer K; Brossart P; Gonzalez-Carmona MA; Strassburg CP; Essler M; Ahmadzadehfar H
Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1207-1214. PubMed ID: 28246882
[TBL] [Abstract][Full Text] [Related]
16. Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.
Bodei L; Cremonesi M; Grana CM; Fazio N; Iodice S; Baio SM; Bartolomei M; Lombardo D; Ferrari ME; Sansovini M; Chinol M; Paganelli G
Eur J Nucl Med Mol Imaging; 2011 Dec; 38(12):2125-35. PubMed ID: 21892623
[TBL] [Abstract][Full Text] [Related]
17. Does the pretherapeutic tumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate?
Ezziddin S; Lohmar J; Yong-Hing CJ; Sabet A; Ahmadzadehfar H; Kukuk G; Biersack HJ; Guhlke S; Reichmann K
Clin Nucl Med; 2012 Jun; 37(6):e141-7. PubMed ID: 22614212
[TBL] [Abstract][Full Text] [Related]
18. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
Parghane RV; Talole S; Prabhash K; Basu S
Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
[TBL] [Abstract][Full Text] [Related]
19. Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE.
Gupta SK; Singla S; Bal C
Cancer Biother Radiopharm; 2012 Nov; 27(9):593-9. PubMed ID: 23009580
[TBL] [Abstract][Full Text] [Related]
20. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
